Company Overview and News

 
Semiconductor - Communications Stock Outlook: Growth Prospects Solid

2018-09-25 zacks
The Semiconductor – Communications Industry includes companies that provide analog, mixed-signal and digital signal processing integrated circuits to consumer, mobile, desktop, automotive, industrial, IoT, wearable devices and other markets.
DSPG CY NPTN

153
Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL

 
NPTN / NeoPhotonics Corp, 10-Q (Quarterly Report)

2018-08-06 sec.gov
Document Table of Contents
NPTN

 
NPTN / NeoPhotonics Corp, 8-K (Current Report)

2018-08-06 sec.gov
Document UNITED STATES
NPTN

11
Intevac: Mean Reverting Value With Material Growth Opportunities

2018-07-03 seekingalpha - 1
The Thin-film equipment division designs, manufacture, and services capital equipment that deposit thin films on the surface to produce magnetic disks for hard disk drives, centralized storage for cloud computing. Additionally, other applications and a key to material near-term growth include touch panels such as mobile phones' front and back, notebooks, smartwatch, tablets, and automotive monitors.
CYBE ASYS AXTI XCRA ACLS CLFD NPTN KOPN NANO IVAC PRCP COHU ESIO

521
Lumentum: A Diversified Growth Opportunity

2018-06-26 seekingalpha
Its a good bet for someone looking for diversified exposure to several sub-segments within the optical hardware manufacturing space.
AAPL AAOI NPTN

2
NPTN / NeoPhotonics Corp, FORM 8-K (Current Report)

2018-06-11 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
NPTN

2
NPTN / NeoPhotonics Corp, SD

2018-05-31 sec.gov - 1
UNITED STATES SECURITIES
NPTN

44
NeoPhotonics: Be Careful

2018-05-13 seekingalpha
Shares of NeoPhotonics (NYSE:NPTN) have pretty much been rangebound for the better part of the past six months. Bulls would believe that the company is poised to grow substantially once client spending on 100G-plus products gains momentum. That may very well be the case indeed, but there's a major risk factor that the broad swath of long-side investors is probably unaware of that can really hurt NeoPhotonics' business - its massive revenue exposure to Huawei.
OCLR ACIA ZTCOY NPTN

3
NPTN / NeoPhotonics Corp, 10-Q (Quarterly Report)

2018-05-09 sec.gov - 2
Document Table of Contents
NPTN

4
NPTN / NeoPhotonics Corp, 8-K (Current Report)

2018-05-08 sec.gov - 3
Document UNITED STATES
NPTN

13
Fabrinet: Optical Communications Industry Underpriced Due To Unjustified Pessimistic Outlook

2018-05-07 seekingalpha
The optical communications industry continues to increase in size and demand for external manufacturing is becoming more common.
FNSR FN NPTN

4
NPTN / NeoPhotonics Corp, DEFA14A

2018-04-19 sec.gov - 3
UNITED STATES
NPTN

1
NPTN / NeoPhotonics Corp, DEF 14A

2018-04-19 sec.gov
Document Table of Contents SCHEDU
NPTN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NPTN / NeoPhotonics Corp, on message board site Silicon Investor.

Neophotonics(NPTN) Neophotonics(NPTN) Neophotonics(NPTN) The Neptune Society (NPTN) The Neptune Society (NPTN) The Neptune Society (NPTN)
CUSIP: 64051T100